- Home
- INZY vs MFIN Comparison
INZY vs MFIN Comparison
Compare INZY & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- MFIN
- Stock Information
- Founded
- INZY 2015
- MFIN 1995
- Country
- INZY United States
- MFIN United States
- Employees
- INZY N/A
- MFIN N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- MFIN Finance: Consumer Services
- Sector
- INZY Health Care
- MFIN Finance
- Exchange
- INZY Nasdaq
- MFIN Nasdaq
- Market Cap
- INZY 188.2M
- MFIN 190.0M
- IPO Year
- INZY 2020
- MFIN 1996
- Fundamental
- Price
- INZY $2.00
- MFIN $9.03
- Analyst Decision
- INZY Strong Buy
- MFIN
- Analyst Count
- INZY 7
- MFIN 0
- Target Price
- INZY $16.43
- MFIN N/A
- AVG Volume (30 Days)
- INZY 666.9K
- MFIN 73.1K
- Earning Date
- INZY 11-05-2024
- MFIN 02-18-2025
- Dividend Yield
- INZY N/A
- MFIN 4.87%
- EPS Growth
- INZY N/A
- MFIN N/A
- EPS
- INZY N/A
- MFIN 1.69
- Revenue
- INZY N/A
- MFIN $293,257,000.00
- Revenue This Year
- INZY N/A
- MFIN N/A
- Revenue Next Year
- INZY N/A
- MFIN $10.95
- P/E Ratio
- INZY N/A
- MFIN $5.34
- Revenue Growth
- INZY N/A
- MFIN 18.48
- 52 Week Low
- INZY $1.97
- MFIN $6.48
- 52 Week High
- INZY $7.80
- MFIN $10.50
- Technical
- Relative Strength Index (RSI)
- INZY 33.08
- MFIN 38.98
- Support Level
- INZY $2.68
- MFIN $9.09
- Resistance Level
- INZY $3.18
- MFIN $9.56
- Average True Range (ATR)
- INZY 0.23
- MFIN 0.33
- MACD
- INZY -0.01
- MFIN -0.07
- Stochastic Oscillator
- INZY 2.52
- MFIN 25.22
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.